Company Overview of Broad Institute of MIT and Harvard
7 Cambridge Center
Cambridge, MA 02142
Key Executives for Broad Institute of MIT and Harvard
President and Founding Director
Associate Member and Director of Stanley Center for Psychiatric Research
Compensation as of Fiscal Year 2015.
Broad Institute of MIT and Harvard Key Developments
Transposagen, Inc. Licenses Broad Institute CRISPR/Cas9 Technology
Dec 11 15
Transposagen Inc. announced that it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. The CRISPR/Cas9 technology is incorporated into a suite of gene editing offerings that enable drug discovery researchers to create more accurate disease models, both in vitro and in vivo.
Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital
Dec 9 15
Neon Therapeutics announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline. The work of Neon Therapeutics co-founders Catherine J. Wu, M.D., at the Broad Institute and Dana-Farber Cancer Institute, Nir Hacohen, Ph.D., at the Broad Institute and Massachusetts General Hospital, and Ed Fritsch, Ph.D., at the Broad Institute and Dana-Farber Cancer Institute, led to the development of a personalized neoantigen vaccine, which is the foundation for Neon Therapeutics' proprietary lead compound, NEO-PV-01. The project was originated and led by the Broad Institute and was philanthropically funded in part by the Blavatnik Family Foundation. Dana-Farber Cancer Institute is currently enrolling two investigator-initiated trials with additional trials planned. Neon Therapeutics will build upon this research and initiate a company-sponsored clinical trial in 2016.
Beryllium Develops MCL-1 Platform for Structure-Guided Drug Discovery in Collaboration with the Broad Institute of MIT and Harvard
May 27 15
Beryllium announced the development of an MCL-1 platform for structure-guided drug discovery. MCL-1 is one of the top-ten most amplified genes in all of human cancer and is vital to tumor development and cancer progression. In collaboration with the Broad Institute of MIT and Harvard, scientists at Beryllium developed a crystallographic platform for MCL-1 that uses a combination of fusion protein and sequence engineering. Unlike previously available structures based on ligand dependent interactions, the new methods allow for systematic screening against MCL-1 and opens the door to structure based drug design.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries